Ilaria Plantamura
Overview
Explore the profile of Ilaria Plantamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fogazzi V, Kapahnke M, Cataldo A, Plantamura I, Tagliabue E, Di Cosimo S, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358746
Breast cancer that highly expresses human epidermal growth factor receptor 2 (HER2+) represents one of the major breast cancer subtypes, and was associated with a poor prognosis until the introduction...
2.
Pizzamiglio S, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, et al.
Cancer Med
. 2021 Dec;
11(2):332-339.
PMID: 34921525
Background: Neoadjuvant therapy with dual HER2 blockade improved pathological complete response (pCR) rate in HER2-positive breast cancer patients. Nevertheless, it would be desirable to identify patients exquisitely responsive to single...
3.
Cosentino G, Plantamura I, Tagliabue E, Iorio M, Cataldo A
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359591
The clinical management of breast cancer reaches new frontiers every day. However, the number of drug resistant cases is still high, and, currently, this constitutes one of the major challenges...
4.
Plantamura I, Cataldo A, Cosentino G, Iorio M
Int J Mol Sci
. 2020 Dec;
22(1).
PMID: 33375067
Despite its controversial roles in different cancer types, miR-205 has been mainly described as an oncosuppressive microRNA (miRNA), with some contrasting results, in breast cancer. The role of miR-205 in...
5.
Cosentino G, Romero-Cordoba S, Plantamura I, Cataldo A, Iorio M
Cells
. 2020 Sep;
9(9).
PMID: 32972039
Tumor growth and invasion occurs through a dynamic interaction between cancer and stromal cells, which support an aggressive niche. MicroRNAs are thought to act as tumor messengers to "corrupt" stromal...
6.
Cataldo A, Romero-Cordoba S, Plantamura I, Cosentino G, Hidalgo-Miranda A, Tagliabue E, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32806777
: Chemotherapy is still the standard of care for triple-negative breast cancers (TNBCs). Here, we investigated miR-302b as a therapeutic tool to enhance cisplatin sensitivity in vivo and unraveled the...
7.
Cosentino G, Plantamura I, Cataldo A, Iorio M
Int J Mol Sci
. 2019 Oct;
20(20).
PMID: 31627322
Oxidative stress is a pathological condition determined by a disturbance in reactive oxygen species (ROS) homeostasis. Depending on the entity of the perturbation, normal cells can either restore equilibrium or...
8.
Plantamura I, Cosentino G, Cataldo A
Front Oncol
. 2018 Sep;
8:352.
PMID: 30234015
MicroRNAs are a class of small non-coding regulatory RNAs playing key roles in cancer. Breast cancer is the most common female malignancy worldwide and is categorized into four molecular subtypes:...
9.
Cataldo A, Piovan C, Plantamura I, DIppolito E, Camelliti S, Casalini P, et al.
Oncotarget
. 2018 Jul;
9(46):27920-27928.
PMID: 29963251
Trastuzumab is the standard treatment for HER2+ breast cancer (BC) patients, and even though it significantly improved their clinical outcome, 50% of them do not benefit from this drug and...
10.
Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, et al.
Oncotarget
. 2016 Sep;
7(43):69649-69665.
PMID: 27626701
CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast...